German researchers want to develop a new vaccine against the dangerous infectious disease Berlin (AP) — in the view of the world’s growing number of tuberculosis cases. According to animal studies could first clinical tests on humans (phase I-study) in mid-2005 spokesperson for the society for biotechnology research on Monday start, said Thomas Gazlig,. The Berlin Max Planck Institute has developed the potential new vaccine for infection biology. At best, could be the way in five years on the market, said Gazlig in advance of World TB Day (March 24). According to the Berlin Max Planck Institute, worldwide 50 million people with a form of tuberculosis are infected, which is no longer to be treated with conventional means. Is the resistance of the tuberculosis strains to common antibiotics spreading in Eastern Europe. When the new vaccination Berlin researchers rely on genetically modified variants of Lebendimpfstoffs BCG used since 1921. Stefan Kaufmann, Director of the Berlin Max Planck Institute said with the conventional vaccination, children would while protected from certain forms of tuberculosis, against the adult pulmonary tuberculosis BCG does not work but at all. The new vaccine have already led to a more effective immune response in preclinical trials. The development of the vaccine is financed by the Federal Research Ministry. According to the World Health Organisation (WHO), about two million people die each year from tuberculosis. In particular India, as well as countries in Africa and Latin America are affected. But also in Germany, tuberculosis is not eradicated, each year approximately 7500 cases occur.